Real-World Evidence (RWE) Solutions Market Worth $1.64 Billion by 2024, Growing at a CAGR of 15% from 2019

With the growing need to achieve better value for healthcare, the importance of real-world evidence (RWE) as a decision-making tool and an important part of drug development and commercialization has also raised. Pharma and biopharma companies now recognize the need to get a better understanding and stronger evidence of product performance, clinical value and cost effectiveness outside the controlled environment and homogeneous setting of a clinical trial i.e. Randomized Clinical Trials (RCT) to inform decision making processes.

A report into the projected growth of the current Real-World Evidence (RWE) solutions market by Meticulous Research® has produced lucrative forecasts for the industry. By 2024, it’s expected to have grown at a compound annual growth rate (CAGR) of 15.0%, reaching $1.64 billion.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=4954

Future Outlook: Real-World Evidence (RWE) Solutions Market to Witness Lucrative Growth during the Forecast Period (2019-2024)

In a report published today, Meticulous Research® has stated that the size of the global Real-World Evidence (RWE) solutions market will reach an impressive $1.64 billion by 2024.

The researchers suggest that the growth of Real-World Evidence (RWE) solutions market will be driven by factors including the rising geriatric population and burden of chronic diseases, shift towards value-based care, increasing R&D expenditure by the life sciences industry, delays in drug development and the subsequent increase in development costs, and expanding use of RWE for regulatory decision making.

The report states that data sets currently account for the largest share of the total market and is expected to grow at a CAGR of 13.8% from 2019 to 2024. Meticulous Research® identified as to why this segment will continue dominating over real-world evidence services: “Due to increasing need for additional insights on epidemiology, compliance, adherence and costs in a realistic environment; growing amount of medical data generated in hospitals; increasing dependence of outcome-based studies on real-world data; and rising demand for information by the payers, regulatory bodies and providers regarding drug safety.”

We are in the phase of updating this report by analysing the impact of COVID-19 on this market. Speak to out Analyst to know more- https://www.meticulousresearch.com/speak-to-analyst/cp_id=4954

Based on application, drug development and approvals commanded the largest share in 2018 owing to significant demand of RWD and RWE to accelerate drug discovery and development, increasing investment by biopharmaceutical companies in R&D, and growing inclination of regulatory bodies towards RWE. However, adoption of RWE for market access and reimbursement/coverage decisions is expected to witness fastest growth.

Pharmaceutical, biotechnology & medical device companies were the leading adopters of real-world evidence solutions in 2018 and are also expected to register fastest growth during the forecast period. This is attributed to the increasing importance of RWE studies in drug development and approvals, growing focus to avoid costly drug recalls, increasing need to assess drug performance in real-world settings, and growing emphasis on drug safety and post-market surveillance.

The report further speculates that North America is currently home for most of the real-world evidence solutions providers and is the leading adopter of RWD and RWE. The largest as well as fastest growth of this region is supported by significant availability of real-world data sets, growing focus on value-based care, rising R&D expenditure by the biopharma companies, greater emphasis on early drug/device development and approvals, stringent regulations for drug approvals, and favorable government policies (implementation of 21st Century Cures Act (December 2016) and FDA’s new 2019 strategic Framework for RWE (December 2018) in the U.S).

Quick Buy – RWE Solutions Market Research Report: https://www.meticulousresearch.com/buy_now.php?pformat=253&vformat=751

Real World Evidence (RWE) Solutions Market by Component (RWD, EMR, Claim, Patient Registry, Pharmacy, Service), Application (Oncology, CVD, Neuro, Infection, Regulatory), End User (Pharma, Biotech, Medical Devices, Payers, Healthcare) - Global Forecast to 2024

The key players operating in the global real-world evidence (REW) solutions market are Anthem, Inc., Clinigen Group plc, Cognizant, IBM Corporation, ICON plc, IQVIA, Optum,Inc., Oracle Corporation, PAREXEL International Corporation, PerkinElmer Inc., Pharmaceutical Product Development, LLC., SAS Institute Inc., and Syneos Health among others.

TOP 10 COMPANIES IN REAL WORLD EVIDENCE SOLUTIONS MARKET
https://meticulousblog.org/top-10-companies-in-real-world-evidence-solutions-market/

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

This release was published on openPR.